Detailed Narrative
Sun Pharmaceutical Industries Limited delivered a strong performance in Q3 FY25, with consolidated sales reaching INR134,369 million, marking a 10.5% year-on-year increase. Excluding milestone income, the underlying sales growth was 8.9%. The company's profitability saw a significant boost, with EBITDA (including other operating revenues) growing by 15.3% to INR40,090 million, resulting in a healthy EBITDA margin of 29.3%. Adjusted net profit, excluding an exceptional item📎 of INR3,162 million related to an opioid litigation settlement, surged by 24.1% to INR32,196 million. The effective tax rate for the quarter was 14.7%, and EPS stood at INR13.4 per share. For the nine-month period, gross sales grew 9.1% to INR392,257 million, and adjusted net profit was up 24.3% to INR90,953 million. The Board declared an interim dividend of INR10.50 per share for FY25, an increase from INR8.50 in the prior year, reflecting confidence in the company's financial health and future prospects.
The India business was a key growth engine, with formulation sales of INR43,004 million, demonstrating a robust 13.8% growth over Q3 last year and contributing 32% to total consolidated sales. Sun Pharma maintained its leadership position in the Indian pharmaceutical market with an 8.2% market share, outperforming the overall market. This growth was primarily driven by increased volumes and 12 new product launches during the quarter, with approximately 50-55% of the growth attributed to these factors, and the remainder to price adjustments. In contrast, the U.S. business experienced a marginal 1% decline in sales to US$474 million, mainly due to lower sales of Lenalidomide, although this was largely mitigated by strong performance in the specialty business and the launch of 4 new generic products.
Beyond India and the U.S., the Emerging Markets (EM) and Rest of the World (ROW) segments also showed positive momentum. EM revenues grew 10.1% to US$277 million, with an underlying constant currency growth of 14% year-on-year. ROW formulation revenues increased by 21% to US$259 million. Global Specialty sales were particularly strong, rising 24.8% to US$370 million, driven by key brands like ILUMYA, CEQUA, ODOMZO, and WINLEVI. The company's consolidated investment in R&D for Q3 FY25 was INR8,450 million, representing 6.3% of sales, with specialty R&D accounting for 41% of this spend. However, due to delays in finalizing clinical trial protocols and approvals, the R&D expenditure for the full year FY25 is now expected to be less than 7% of sales, a revision from earlier guidance.
Management expressed a generally bullish outlook, particularly on the continued growth of specialty products and the sustained performance of the India business. They highlighted the strategic importance of their consumer health business, which includes nearly US$200 million in emerging markets. While acknowledging challenges in the generic segment, especially in Japan due to pricing pressure, the company remains focused on expanding its specialty portfolio. Ongoing efforts are directed at bringing FDA-flagged facilities, such as Halol, back into compliance to support future product launches and business expansion.
During the Q&A, management addressed concerns regarding the impact of potential U.S. government policy changes, noting that these were still vague and difficult to plan for. They clarified that the lumpy nature of milestone income from partners is tied to sales achievements rather than seasonal patterns. The company also provided an update on the Antibe acquisition, stating that the FDA is expecting further studies to lift the clinical hold on its lead drug. The lower distribution costs in Q3 were primarily attributed to minimized pre-launch expenses for LEQSELVI in the U.S. The maximum annual PLI benefit was indicated to be INR200 crores. Overall, Sun Pharma continues to prioritize strategic value-add options, with a general focus on specialty products for future capital deployment.